. 2020 Feb 6;102(2 Suppl):3–24. doi: 10.4269/ajtmh.19-0620

Table 3.

Advantages and disadvantages of the two ivermectin regimens for malaria being tested in clinical trials through 2023

	Advantages	Disadvantages
3 × 300 μg/kg daily doses per month “3 × 300”	Longer effect and, therefore, higher efficacy	Lower coverage expected (as evidenced in malaria community has experience with SMC and MDA 3-dose regimens)
3 × 300 μg/kg daily doses per month “3 × 300”	Longer effect and, therefore, higher efficacy	May have longer regulatory pathway, requiring additional safety and pediatric data for approval of a new dose and regimen
1 × 400 μg/kg dose per month “1 × 400”	Expected increased uptake and scalability with a single dose	Shorter duration of effect and, therefore, potentially lower impact
	Dose already approved under European Medicines Agency, in France and the Netherlands for LF MDA, may facilitate the regulatory process	Dose is used only in a few countries with LF
	Simpler to consider under national program guidelines and potential for synergies with NTD programs
	Similarity to NTD programs could enhance community acceptance.

LF = lymphatic filariasis; MDA = mass drug administration; NTD = neglected tropical disease.